The United States Food and Drug Administration (USFDA) has retained the Official Action Indicated (OAI) status for Goa Plant - I (Finished Dosages Facility) of Indoco Remedies. The facility was inspected by the USFDA in January 2019. The plant currently supplies against one approved ANDA and has four ANDAs pending for approval.
Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs) in India.